"A general rule of thumb
[is] that each 1% in generic market share shift would result in about $1
million reduction in drug spend. Until the biosimilars can offer this type of
savings, the incentive for payers to move will not be there, and, thereby, they
will not persuade prescribers to switch."
— Ryan Cox,
R.Ph., vice president, access experience team at Precision for Value, spoke
with AIS's RADAR on Specialty
Pharmacy about the FDA's final interchangeability guidance for
biosimilars, and why payers still might have hurdles to overcome in
implementing biosimilar use.
No comments:
Post a Comment